Y-mAbs Therapeutics Inc
NASDAQ:YMAB
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.44
18.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Y-mAbs Therapeutics Inc
Wall Street
Price Targets
YMAB Price Targets Summary
Y-mAbs Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
YMAB
is 21.33 USD
with a low forecast of 11.11 USD and a high forecast of 27.3 USD.
YMAB Last Price Targets
Y-mAbs Therapeutics Inc
The latest public price target was made on Nov 11, 2024 by
Etzer Darout
from
BMO Capital
,
who expects
YMAB
stock to
rise by 131%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Etzer Darout
BMO Capital
|
24
USD
Upside 131% |
1 week ago
Nov 11, 2024
|
Y-mAbs Therapeutics (YMAB) PT Lowered to $24 at BMO Capital
StreetInsider
|
Nicole Germino
Truist Financial
|
21
USD
Upside 103% |
4 months ago
Jun 28, 2024
|
Truist Securities Starts Y-mAbs Therapeutics (YMAB) at Buy
StreetInsider
|
|
Robert Burns
H.C. Wainwright
|
22
USD
Upside 112% |
6 months ago
May 10, 2024
|
Y-mAbs Therapeutics price target raised to $22 from $21 at H.C. Wainwright
TheFly
|
|
Etzer Darout
BMO Capital
|
26
USD
Upside 151% |
7 months ago
Apr 5, 2024
|
BMO Capital on Y-mAbs Therapeutics (YMAB): 'Radiopharma Is Hot & SADA De-Risking Would Unlock Value'
StreetInsider
|
YMAB)to Outperform
Wedbush
|
13
USD
Upside 25% |
1 year ago
May 10, 2023
|
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is YMAB's stock price target?
Price Target
21.33
USD
According to Wall Street analysts, the average 1-year price target for
YMAB
is 21.33 USD
with a low forecast of 11.11 USD and a high forecast of 27.3 USD.
What is Y-mAbs Therapeutics Inc's Revenue forecast?
Projected CAGR
13%
The
compound annual growth rate
of Y-mAbs Therapeutics Inc's revenue for the next 3 years is
13%.
You don't have any saved screeners yet
